New clinical trials showed that Pfizer’s COVID-19 vaccine elicits “100% efficacy and robust antibody responses” in adolescents from 12 to 15 years old, the drug company announced. The trial included 2,260 participants; the results are even better than earlier responses from participants ages 16 to 25.
Pfizer and its vaccine partner BioNTech said they will submit the results “as soon as possible” to the U.S. Food and Drug Administration and the European Medicines Agency, asking regulators to expand their authorizations for the vaccine’s use in young people.
Pfizer will submit the data “in the coming weeks,” Pfizer CEO and Chairman Albert Bourla said in a news release about the trial. Calling the results encouraging, he added that the company is acting “with the hope of starting to vaccinate this age group before the start of the next school year.”
Scroll down for more from DA
